Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Forbion Capital Fund III C.V. / agreement with Forbion Cap.

<< Previous

Bullboard Posts

Next >>

Comment by drippingsnoton Sep 13, 2020 11:35am

50 Views

Post# 31549825

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Forbion Capital Fund III C.V. / agreement with Forbion Cap.

Hope this helps you with your calculations Snowballgrowth ... for more information you may need to go directly to a company representative.

{Knight invested a cumulative $128M and received distributions of $69.3M, including a realized gain of $22.4M.}

{The fair value of the strategic fund investments as at June 30, 2020 is $132.2M representing a cumulative unrealized gain of $51.0M}

{As at June 30, 2020, $30.1M commitment was remaining}

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions